Pathophysiological mechanisms of diabetic angiopathy

被引:63
作者
Hammes, HP [1 ]
机构
[1] Univ Heidelberg, Fac Clin Med Mannheim, Univ Hosp Mannheim, Med Dept 5, D-68167 Mannheim, Germany
关键词
diabetic complications; pathobiochemistry; chronic hyperglycemia; angiopathy;
D O I
10.1016/S1056-8727(02)00275-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The sequelae of chronic hyperglycemia in diabetes of all phenotypes are divided into microvascular and macrovascular complications. Microvascular disease causes blindness, renal failure, and neuropathy, and diabetes-accelerated macrovascular disease causes excessive risk for myocardial infarction, stroke, and lower limb amputation. The link between chronic hyperglycemia and vascular damage has been established by four independent biochemical abnormalities: increased polyol pathway flux, increased formation of advanced glycation end-products (AGEs), activation of protein kinase C (PKC), and increased hexosamine pathway flux. These seemingly unrelated pathways have an underlying common denominator: overproduction of superoxide by the mitochondrial electron transport chain. Mitochondrial reactive oxygen species (ROS) partially inhibit the glycolytic enzymes glyceraldehyde-3-phosphate dehydrogenase, which diverts increased substrate flux from glycolysis to pathways of glucose overutilization. Preliminary experimental evidence in vivo suggests that this new paradigm provides a novel basis for research and drug development. (C) 2003 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:16 / 19
页数:4
相关论文
共 22 条
[1]   Biochemistry and molecular cell biology of diabetic complications [J].
Brownlee, M .
NATURE, 2001, 414 (6865) :813-820
[2]   Hyperglycemia-induced mitochondrial superoxide overproduction activates the hexosamine pathway and induces plasminogen activator inhibitor-1 expression by increasing Sp1 glycosylation [J].
Du, XL ;
Edelstein, D ;
Rossetti, L ;
Fantus, IG ;
Goldberg, H ;
Ziyadeh, F ;
Wu, J ;
Brownlee, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (22) :12222-12226
[3]  
Elhadd T A, 1999, Diabetes Care, V22, P528
[4]   Gliclazide improves anti-oxidant status and nitric oxide-mediated vasodilation in Type 2 diabetes [J].
Fava, D ;
Cassone-Faldetta, M ;
Laurenti, O ;
De Luca, O ;
Ghiselli, A ;
De Mattia, G .
DIABETIC MEDICINE, 2002, 19 (09) :752-757
[5]   BCL-2 expression or antioxidants prevent hyperglycemia-induced formation of intracellular advanced glycation endproducts in bovine endothelial cells [J].
Giardino, I ;
Edelstein, D ;
Brownlee, M .
JOURNAL OF CLINICAL INVESTIGATION, 1996, 97 (06) :1422-1428
[6]   Causes of blindness in Hessia [J].
Gräf, M ;
Halbach, E ;
Kaufmann, H .
KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 1999, 215 (01) :50-55
[7]  
Hsueh Willa A., 1998, American Journal of Medicine, V105, p4S, DOI 10.1016/S0002-9343(98)00205-8
[8]   Blindness incidence in Germany -: A population-based study from Wurttemberg-Hohenzollern [J].
Krumpaszky, HG ;
Lüdtke, R ;
Mickler, A ;
Klauss, V ;
Selbmann, HK .
OPHTHALMOLOGICA, 1999, 213 (03) :176-182
[9]   Complications co-morbidity, and blood glucose control in type 2 diabetes mellitus patients in Germany -: results from the CODE-2™ study [J].
Liebl, A ;
Neiss, A ;
Spannheimer, A ;
Reitberger, U ;
Wieseler, B ;
Stammer, H ;
Goertz, A .
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2002, 110 (01) :10-16
[10]   Atherosclerosis [J].
Lusis, AJ .
NATURE, 2000, 407 (6801) :233-241